Tags : Provisional

Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque

Shots: The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW reSURFACE 1 & reSURFACE 2 studies result: @12wks. PASI 75 (75%); @28wks. PASI 90 (54%), PASI 100 (29%); well tolerated; low AEs & discontinuation rates Ilumetri (tildrakizumab, SC, […]Read More